公开(公告)号：US20210403522A1

公开(公告)日：2021-12-30

申请号：US17468907

申请日：2021-09-08

Applicant: Howard Hughes Medical Institute

Inventor： Scott Sternson ,  Peter Lee ,  Christopher Magnus

IPC: C07K14/47 ,  A61K38/01 ,  A61K38/17 ,  C07K14/705 ,  C12N15/00 ,  C12N15/09

Abstract: This document relates to materials and methods for controlling ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.

公开(公告)号：US10981962B2

公开(公告)日：2021-04-20

申请号：US16544738

申请日：2019-08-19

Applicant: Howard Hughes Medical Institute

Inventor： Scott Sternson ,  Peter Lee ,  Christopher Magnus

IPC: C07K14/705 ,  C07K19/00 ,  C07K14/47 ,  A61K38/01 ,  A61K38/17 ,  C12N15/00 ,  C12N15/09

Abstract: This document relates to materials and methods for controlling ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.

公开(公告)号：US11084853B2

公开(公告)日：2021-08-10

申请号：US15644295

申请日：2017-07-07

Applicant: Howard Hughes Medical Institute

Inventor： Scott Sternson ,  Peter Lee ,  Christopher Magnus

IPC: C07K14/705 ,  C07K19/00 ,  C07K14/47 ,  A61K38/01 ,  A61K38/17 ,  C12N15/00 ,  C12N15/09

Abstract: This document relates to materials and methods for controlling ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.

公开(公告)号：US20180009862A1

公开(公告)日：2018-01-11

申请号：US15644295

申请日：2017-07-07

Applicant: Howard Hughes Medical Institute

Inventor： Scott Sternson ,  Peter Lee ,  Christopher Magnus

IPC: C07K14/47 ,  C07K14/705 ,  A61K38/01 ,  A61K38/17 ,  C12N15/09 ,  C12N15/00

CPC classification number: C07K14/4713 ,  A61K38/012 ,  A61K38/1709 ,  C07K14/4702 ,  C07K14/705 ,  C07K14/70571 ,  C07K2319/00 ,  C07K2319/03 ,  C12N15/00 ,  C12N15/09

Abstract: This document relates to materials and methods for controlling ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.

公开(公告)号：US11124554B2

公开(公告)日：2021-09-21

申请号：US16868205

申请日：2020-05-06

Applicant: Howard Hughes Medical Institute

Inventor： Scott Sternson ,  Peter Lee ,  Christopher Magnus

IPC: C07K14/705 ,  C07K19/00 ,  C07K14/47 ,  A61K38/01 ,  A61K38/17 ,  C12N15/00 ,  C12N15/09

Abstract: This document relates to materials and methods for controlling ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.

公开(公告)号：US20210206831A1

公开(公告)日：2021-07-08

申请号：US17146906

申请日：2021-01-12

Applicant: Howard Hughes Medical Institute

Inventor： Scott Sternson ,  Peter Lee ,  Christopher Magnus

IPC: C07K14/705 ,  A61K48/00

Abstract: This document relates to materials and methods for modulating ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.

公开(公告)号：US20240002463A1

公开(公告)日：2024-01-04

申请号：US18140403

申请日：2023-04-27

Applicant: Howard Hughes Medical Institute

Inventor： Scott Sternson ,  Christopher Magnus

IPC: C07K14/705 ,  C12N5/0793 ,  A61P39/02

CPC classification number: C07K14/705 ,  A61P39/02 ,  C12N5/0619

Abstract: This disclosure describes a number of chemogenetic receptors that bind an ingested substance that reinforces its own ingestion or administration (e.g., an addictive drug) and, upon binding of the molecule, modulate the function of a cell.

公开(公告)号：US10961296B2

公开(公告)日：2021-03-30

申请号：US16186122

申请日：2018-11-09

Applicant: Howard Hughes Medical Institute

Inventor： Scott Sternson ,  Peter Lee ,  Christopher Magnus

IPC: C07K14/705 ,  A61K48/00

Abstract: This document relates to materials and methods for modulating ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.

公开(公告)号：US20200377566A1

公开(公告)日：2020-12-03

申请号：US16868205

申请日：2020-05-06

Applicant: Howard Hughes Medical Institute

Inventor： Scott Sternson ,  Peter Lee ,  Christopher Magnus

IPC: C07K14/47 ,  C07K14/705 ,  A61K38/01 ,  A61K38/17 ,  C12N15/00 ,  C12N15/09

Abstract: This document relates to materials and methods for controlling ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.

公开(公告)号：US20190169264A1

公开(公告)日：2019-06-06

申请号：US16186122

申请日：2018-11-09

Applicant: Howard Hughes Medical Institute

Inventor： Scott Sternson ,  Peter Lee ,  Christopher Magnus

IPC: C07K14/705 ,  A61K48/00

Abstract: This document relates to materials and methods for modulating ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.